hVIVO plc Finance Director (2829H)
31 Juillet 2019 - 8:03AM
UK Regulatory
TIDMHVO
RNS Number : 2829H
hVIVO plc
31 July 2019
hVIVO plc
("hVIVO" or the "Company")
Finance Director
London, UK - 31 July 2019: hVIVO plc (AIM: HVO), an industry
leading clinical development services business pioneering human
disease models based upon viral challenge, announces that Shelley
Fraser, Finance Director and Company Secretary, is leaving
hVIVO.
The Board has appointed Anesh Patel as Interim Finance Director
and Company Secretary with immediate effect. A further announcement
will be made in due course to confirm the appointment of Shelley's
successor.
Anesh was previously Director, Corporate Finance at hVIVO, a
role he has held since April 2016. Prior to this he spent seven
years in investment banking providing corporate finance advisory
services to a range of clients having started his professional
career with Ernst & Young in 2004 where he qualified as a
Chartered Accountant. He graduated from University College London
(UCL) and holds an MSc (Hons) degree in Mathematics with
Economics.
Dr Trevor Phillips, Executive Chairman, commented:
"On behalf of the Board I would like to thank Shelley for her
contribution to the Company and we wish her success in the future.
We are pleased to be able to appoint Anesh as interim Finance
Director who has worked at the Company for a number of years and
worked closely with Shelley and the Finance team to ensure a smooth
and effective transition."
For further information please contact:
hVIVO plc
Trevor Phillips (Executive Chairman) +44 207 756 1300
Fleur Wood (EVP, Investor Relations & Communications)
Numis Securities Limited +44 207 260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial
platform to accelerate drug and vaccine development in respiratory
and infectious diseases. Leveraging human disease models in flu,
RSV, HRV and respiratory indications, the hVIVO platform captures
disease in motion, illuminating the entire disease life cycle from
healthy to sick and back to health. Based in the UK, market leader
hVIVO has conducted more than 50 clinical studies and inoculated
over 2500 volunteers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALBLLXKDFBBBK
(END) Dow Jones Newswires
July 31, 2019 02:03 ET (06:03 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024